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Low molecular weight heparin-induced skin
necrosis—a systematic review
Abstract Background: Low molec-
ular weight heparins (LMWHs) are
currently used as a standard for anti-
thrombotic therapy. Skin necrosis
caused by LMWH is a rare and
probably under-reported complica-
tion. The aim of our systematic
review is to analyse the present
literature for cases of LMWH-induced
skin necrosis, emphasising the patho-
genesis, clinical pattern, and man-
agement of this rare side effect.
Methods: We performed a Medline
literature search (PubMed database)
and manual cross-referencing to
identify all articles related to LMWH-
induced skin necrosis. Data were
analysed for type of LMWH used,
time until skin necrosis occurred,
localisation, size, laboratory findings,
switch anticoagulant, complications,
and outcome. Additionally, the case
of a patient from our hospital is
presented. Results: We included a
total of 20 articles (21 cases) reporting
on LMWH-induced skin necrosis.
Skin necrosis occurred locally and
distant from the injection site.
Heparin-induced antibodies were fre-
quently observed (positive 9/11 arti-
cles, negative 2/11). However, severe
thrombocytopenia (platelet count
<100,000 cells/ml) occurred in only
four cases, while platelet count re-
mained normal in 50% of the cases.
After patients had been switched to
other anti-thrombotic drugs, the clin-
ical course was usually benign; how-
ever, reconstructive surgery was
necessary in two cases. Conclusion:
LMWH-induced skin necrosis may
occur as part of the heparin-induced
thrombocytopenia (HIT) syndrome,
but other pathomechanisms, including
allergic reactions and local trauma,
may also be involved. When HIT is
excluded, unfractionated heparin is a
safe switch anticoagulant. Otherwise,
non-heparin preparations such as hi-
rudin or fondaparinux should be
preferred.
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Introduction
Heparin preparations have been successfully used for the
prevention and treatment of venous thromboembolism for
more than 50 years. Despite several new anticoagulant
drugs currently in development, low molecular weight hep-
arins (LMWHs) remain the standard for the prophylaxis of
venous thromboembolism in most surgical units [1, 2].
LMWHs have been increasingly advocated on the basis
of lower risk of bleeding and easier administration than
unfractionated heparin (UFH) [3, 4]. Certain side effects,
such as heparin-induced thrombocytopenia, heparin-induced
osteoporosis, skin irritations and necrosis, may occur less
often with LMWH than with UFH [5–7]. Skin necrosis
following LMWH administration is rare, even though the
true incidence is probably underestimated due to under-
reporting [8].
In this systematic review of the literature, we present all
published cases of LMWH-induced skin necrosis and
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discuss the possible pathomechanisms, clinical appearance
and therapeutic options.
Methods
To ensure high methodological quality, we adhered to the
criteria for systematic review outlined by McAlister et al.
[9]. A Cochrane database search revealed that no com-
parative trials, no case series and no systematic review of
articles had been performed. The Medline/PubMed Data-
base was used in the search for relevant literature on low
molecular weight-induced skin necrosis. The present lit-
erature review also included EMBASE (Elsevier), which
contains journals not covered by Medline. The terms
“heparin”, “low molecular weight heparin”, “LMWH”,
“skin”, “skin reaction”, and “skin necrosis” were used in
various combinations. English, German, and French arti-
cles were included. The search terms were identified in the
title, abstract, or medical subject heading (MeSH). We also
used manual cross-referencing to detect further publica-
tions on low molecular weight heparin-induced skin necro-
sis. We applied the following exclusion criteria: articles on
side effects of other anti-thrombotic drugs (unfractionated
heparin, warfarin), review articles, skin necrosis caused by
underlying immunological diseases (anti-phospholipid syn-
drome). Additionally, one case at our hospital was in-
cluded. The articles were analysed for the following data:
patient age and gender, previous heparin exposure, type of
LMWH, time from first LMWH administration until onset
of skin necrosis, dose, site of necrosis (local versus distant),
result of skin biopsy, coagulation state, concomitant throm-
bocytopenia and heparin-induced antibody reaction, throm-
boembolism, therapy of LMWH-induced skin necrosis,
and switch anticoagulant.
Results
Case report
A57-year-oldmale patient (obese, bodymass index36kg/m2)
was admitted to our hospital with multiple injuries includ-
ing mild traumatic brain injury, blunt thoracic trauma with
multiple rib fractures and haematopneumothorax on the
left side, malleolar fracture, and unstable fracture of the
lumbar spine. Past medical history revealed a sleep apnoea
syndrome.
Thromboprophylaxis was started with 15,000 IU/24 h
of UFH intravenously after spinal stabilisation (posterior
instrumentation with fixateur interne), which was per-
formed on day 3 following admission. After 48 h the pa-
tient was transferred from the intensive care unit to the
regular ward, and thromboprophylaxis was switched to
LMWH (dalteparin, 5,000 IU s.c./24 h). The injection sites
were located beside the umbilicus, in the abdominal wall.
After 8 days of LMWH administration, we observed a
progressive, painful erythematous lesion at the injection
sites, and, within hours, areas of necrotic skin developed
(Fig. 1). The size of the necrosis was approximately 3 cm in
diameter. Coagulation tests and platelet count were normal.
Heparin platelet factor-4 (HPF-4) antibody testing was
negative by enzyme-linked immunosorbent assay (ELISA).
Therefore, we decided to switch anticoagulant therapy to
UFH intravenously until the patient’s discharge, since he
was at high risk for postoperative thromboembolism. The
following course was uneventful, and the necrotic plaques
disappeared within 1 week. Subsequently, anterior stabili-
sation of the spine fracture was successfully performed,
and the patient was discharged to a rehabilitation centre
without further complications.
Systematic review
The search terms used in various combinations resulted in
a total of 247 articles on 20 March 2004. Of these, we
identified 20 reported cases of LMWH-induced skin ne-
crosis (Table 1) [10–28]. Thus, a total of 21 cases was re-
viewed, including the case from our clinic. The articles were
published between 1987 and 2003.
LMWH-induced skin necrosis occurred in 11 female
and ten male patients (mean age 62±13 years, range 34–87
years; Table 1). Indication for anti-thrombotic therapy
was prophylaxis of thromboembolism (n=13; postoperative
thromboprophylaxis: n=8/13), treatment of established ve-
nous thromboembolism (n=6), acute coronary syndrome
(n=1) and atrial fibrillation (n=1).
While in ten articles previous heparin exposure was not
reported or was unknown, 11 reports confirmed previous
heparin exposure (subcutaneous UFH n=3, systemic intra-
venous UFH n=4, both subcutaneous and intravenous UFH
n=2, LMWH n=2). In most cases, previous exposure to
heparin occurred a few days before LMWH administration
Fig. 1 Peri-umbilical skin necrosis (approximately 3 cm in diameter)
at the site of LMWH administration
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and consequent onset of skin necrosis; however, in three
cases heparin exposure dated back several years [17, 22, 24].
LMWH preparations included dalteparin (9/21), enox-
aparin (6/21), tinzaparin (1/21), tedelparin (1/21), certoparin
(1/21), nadroparin (1/21) and LMW heparin–dihydroergot-
amine (1/21). In one case the LMWH preparation was not
specified [18]. The daily LMWH dose was reported in 18 ar-
ticles and ranged from 2,000 IU to 5,000 IU anti-factor Xa
(mean dose 4,300±1,355 IU). In one case, a daily dose of
anti-factor Xa dalteparin was applied for 5 days because of
established deep venous thrombosis [27].
The average time between first administration of LMWH
and onset of skin necrosis was 7.6±3.4 days (range 1–17
days). The first symptoms were usually described as ery-
thematous, subcutaneous lesions with oedema and pain at
the injection sites. Subsequently, bullous transformation
was observed before full-skin necrosis occurred. Biopsies
of these urticarial plaques with a necrotic-haemorrhagic
centre were obtained in ten cases and showed epidermal
necrosis with an inflammatory reaction and microvascular
thrombi in dermal vessels. The size of the necrotic areas
varied, but generally appeared small and circumscribed,
with a maximum diameter of a few centimetres. Occasion-
ally, the skin necrosis enlarged to more than 10 cm [11, 13,
14, 19, 23], in one case involving 6% of the body surface
area [24].
Two different patterns of LMWH-induced skin necrosis
were observed: The majority of the lesions (16/21) oc-
curred locally at the injection site (abdominal wall, thigh,
arm). Less frequently (5/21), other anatomical areas distant
from the injection site were affected [13, 18, 19, 26, 27].
Table 1 Reported cases of LMWH-induced skin necrosis. Time
indicates time from first administration of LMWH until onset of
necrosis. Mild thrombocytopenia = 100,000 cell/ml–150,000 cell/ml;
severe thrombocytopenia = <100,000 cells/ml. HAT heparin-associated
thrombocytopenia test, BSA body surface area
Author Year LMWH
type
Time
(days)
Site Size HPF-4
antibodies/HAT
Thrombocytopenia Switch
anticoagulant
Cordoliani [10] 1987 Dalteparin 10 Local, thigh Not reported Not reported No UFH s.c.
Montserrat [11] 1990 Dalteparin 10 Local,
abdominal wall
10 cm × 8 cm Not reported No UFH i.v.
Ojeda [12] 1992 Fraxiparin 5 Not reported Not reported Not reported No Coumarin
Balestra [13] 1994 Dalteparin 8 Distant, thigh 13 cm × 6.5 cm Positive Severe Aspirin
Koch [14] 1994 Enoxaparin 10 Local,
abdominal wall
20 cm Not reported No UFH i.v.
Real [15] 1995 Dalteparin 8 Local,
abdominal wall
Not reported Not reported No UFH i.v.,
Coumarin
Fried [16] 1996 Enoxaparin 6 Local, arm 25 mm Not reported No Not reported
Fried [16] 1996 Enoxaparin 10 Local,
abdominal wall
Not reported Not reported Not reported Not reported
Lefebre [17] 1997 Enoxaparin 1 Local, thigh 3 cm Not reported No Not reported
Gibson [18] 1997 Not reported 6 Distant,
multiple
Not reported Negative (HAT) Severe Coumarin
Tietge [19] 1998 Certoparin 17 Distant,
thigh, bilateral
11 cm–15 cm Positive Mild Aspirin
Tonn [20] 1997 Enoxaparin 3 Local, thigh Not reported Positive Severe Coumarin
Plath [21] 1997 Certoparin 10 Local, arm Not reported Positive Severe UFH i.v.
Fureder [22] 1998 Dalteparin 8 Local, thigh 2 cm × 1.5 cm Positive No None
Santamaria [23] 1998 Tedelparine 12 Local,
abdominal wall
15 cm × 4 cm Positive Mild Aspirin
Drew [24] 1999 Tinzaparin 7 Local,
abdominal
wall, hip
6% BSA Not reported Mild None
Walder [25] 2001 Dalteparin 3 Local, thigh 7 cm × 5 cm Positive Mild Hirudin
Ang [26] 2003 Enoxaparin 7 Distant, arm Not reported Not reported Not reported Not reported
Payne [27] 2003 Dalteparin 5 Distant+local Not reported Positive No Coumarin
Fontana [28] 2004 Nadroparin 4 Local,
abdominal wall
7 cm Positive Mild Hirudin
Handschin
(this review)
2004 Dalteparin 8 Local,
abdominal wall
3 cm Negative (ELISA) No UFH i.v.
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These distant manifestations were apparently random in
distribution.
The presence of heparin-induced thrombocytopenia was
analysed by either an ELISA for HPF-4 antibody (n=10) or
a thrombocyte aggregation test [heparin-associated throm-
bocytopenia (HAT) test], n=1). Heparin-dependent platelet
activating antibodies were present in nine out of ten patients.
One study showed a negative thrombocyte aggregation test
[18].
Platelet count was within the normal range in ten cases,
while severe thrombocytopenia occurred in four of 19 pa-
tients (thrombocyte concentration <100,000 cells/ml) [13,
18, 20, 21] and mild thrombocytopenia (thrombocyte con-
centration 100,000 cells/ml–150,000 cells/ml) in five of 19
patients [19, 23–25, 28]. Two articles did not report on
platelet concentrations [16, 26].
Other parameters of coagulation (anti-thrombin III, pro-
tein s, protein c, prothrombin time, activated partial throm-
boplastin time) were normal in 15 cases. Five articles did
not report on the coagulation state [16, 20, 25–27]. In one
case, a patient with a pre-existing anti-thrombin III de-
ficiency and established pulmonary embolism showed a
prolonged activated partial thromboplastin time and a pos-
itive lupus anticoagulant [18].
After diagnosis of LMWH-induced skin necrosis, anti-
thrombotic therapywas switched to coumarin (n=5) [12, 15,
18, 20, 27], unfractionated heparin (n=5, subcutaneous
UFH n=2, intravenous UFH n=3) [10, 11, 14, 21, present
case], aspirin (n=3) [13, 19, 23], and hirudin (n=2) [25, 28].
In two cases, anti-thrombotic therapy was stopped [22, 24],
and in four cases data on anticoagulant switch were not
reported [16, 17, 26].
The clinical course of the skin necrosis was uneventful in
the majority of the cases (19/21) when LMWHwas stopped
and changed to alternative anticoagulatory drugs. However,
one patient with skin necrosis developed deep venous
thrombosis after dalteparin therapy was changed to cou-
marin therapy [12]. Eventually, UFH was given in this case
without further complications. In two cases, surgical ther-
apy was necessary, i.e. debridement of the necrotic skin and
soft tissue followed by reconstructive surgery with a skin
mesh graft [10, 24].
Discussion
Low molecular weight heparins are heterogeneous pre-
parations with individual molecular weights and pharma-
cological profiles. They are manufactured through different
processes by the cutting down of the molecular structure
of unfractionated heparin. The advantages of LMWHs in-
clude a predictable anticoagulant response, making daily
monitoring unnecessary, improved bioavailability, and a
longer half life than UFH. The incidence of skin reactions
caused by unfractionated heparin is estimated to be 0.2%
[29]. Skin necrosis caused by LMWH is rare and has ex-
clusively been reported in anecdotal cases. Several path-
ophysiological mechanisms have been proposed: First,
LMWH-induced skin necrosis was found to be associated
with an established heparin-induced thrombocytopenia (HIT)
syndrome.Here, an antibody–platelet–heparin complex leads
to an activation of the coagulation cascade that results in
microthrombosis of dermal vessels and skin necrosis lo-
cally or distant from the injection site [7]. Second, vasculi-
tis of dermal vessels induced by a type III hypersensitivity
reaction to the LMWH (Arthus phenomenon with deposit
of immunocomplexes on the endothelial structure) has been
proposed as an alternative pathomechanism [30]. Third,
skin necrosis may be the result of repeated local trauma at
the injection site [8]. This non-immunological mechanism
is triggered through an incorrect intradermal administration
of heparin, with local haemorrhage in a tense dermis leading
to pressure on small blood vessels and subsequent necrosis
of the overlying skin [8, 31]. In addition, impaired absorp-
tion of heparin due to poor vascularisation of adipose tis-
sue may augment local skin damage similar to diabetic
lipodystrophy [17].
The switch anticoagulant for patients with LMWH-
induced skin necrosis is not standardised. Apparently, UFH
may be used as an alternative; however, exclusion of a HIT
syndrome is mandatory. Extreme caution has to be taken
when a patient is switched to oral anticoagulants, since
warfarin (coumarin) may lead to venous gangrene in the
presence of a HIT syndrome [32, 33]. Another shortcoming
of coumarin therapy is the fact that the anticoagulatory
effect is reached only after several days, which is un-
favourable for patients with established thrombosis or in
patients at high and middle risk. Safe treatment of all pa-
tients experiencing anticoagulant-induced skin reactions is
feasible, since several anticoagulants are available today
[29]. In established HITsyndrome, a switch from heparin to
hirudin (a direct thrombin inhibitor) is recommended [34,
35]. Fondaparinux, a selective anti-thrombin-dependent in-
hibitor of activated factor X, may be used in patients with
heparin antibodies because it lacks cross-reactivity and does
not lead to platelet activation in serum from patients with
established HIT syndrome [36, 37].
In summary, the present review describes the clinical pat-
tern of LMWH-induced skin necrosis. In the majority of
cases, heparin–platelet antibodies are detectable, indicating
a HIT syndrome, but severe thrombocytopenia with a plate-
let count below 100,000 cells/ml is rare. Furthermore, there
is usually no activation of coagulation, and severe arterial or
venous thromboembolic complications associated with ful-
minant HIT syndrome are exceptional. The outcome of
LMWH-induced skin necrosis is usually benign, but, in
severe cases, surgical therapy may be necessary.
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